EP1180999A4 - RECOMBINANT VACCINE AGAINST BOTULINUM NEUROTOXIN - Google Patents

RECOMBINANT VACCINE AGAINST BOTULINUM NEUROTOXIN

Info

Publication number: EP1180999A4
Authority: EP; European Patent Office
Prior art keywords: vaccine against; botulinum neurotoxin; recombinant vaccine; against botulinum; recombinant
Prior art date: 1999-05-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

EP00932296A

Other languages

German (de)

French (fr)

Other versions

EP1180999A2 (en

Inventor

Leonard A Smith

Michael P Byrne

John L Middlebrook

Hugh Lapenotiere

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

US Army Medical Research and Development Command

Original Assignee

US Army Medical Research and Development Command

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-12

Filing date

2000-05-12

Publication date

2005-03-30

2000-05-12 Application filed by US Army Medical Research and Development Command filed Critical US Army Medical Research and Development Command

2002-02-27 Publication of EP1180999A2 publication Critical patent/EP1180999A2/en

2005-03-30 Publication of EP1180999A4 publication Critical patent/EP1180999A4/en

Status Ceased legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EP00932296A 1999-05-12 2000-05-12 RECOMBINANT VACCINE AGAINST BOTULINUM NEUROTOXIN Ceased EP1180999A4 (en)

Applications Claiming Priority (15)

Application Number	Priority Date	Filing Date	Title
US13386699P	1999-05-12	1999-05-12
US13386899P	1999-05-12	1999-05-12
US13386799P	1999-05-12	1999-05-12
US13386999P	1999-05-12	1999-05-12
US13387399P	1999-05-12	1999-05-12
US13386599P	1999-05-12	1999-05-12
US133866P		1999-05-12
US133868P		1999-05-12
US133873P		1999-05-12
US133867P		1999-05-12
US133869P		1999-05-12
US133865P		1999-05-12
US14619299P	1999-07-29	1999-07-29
US146192P		1999-07-29
PCT/US2000/012890 WO2000067700A2 (en)	1999-05-12	2000-05-12	Recombinant vaccine against botulinum neurotoxin

Publications (2)

Publication Number	Publication Date
EP1180999A2 EP1180999A2 (en)	2002-02-27
EP1180999A4 true EP1180999A4 (en)	2005-03-30

Family

ID=27568892

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP00932296A Ceased EP1180999A4 (en)	1999-05-12	2000-05-12	RECOMBINANT VACCINE AGAINST BOTULINUM NEUROTOXIN

Country Status (5)

Country	Link
EP (1)	EP1180999A4 (en)
JP (1)	JP2004512004A (en)
AU (1)	AU783450B2 (en)
CA (1)	CA2371279A1 (en)
WO (1)	WO2000067700A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7227010B2 (en) *	1993-09-21	2007-06-05	United States Of America As Represented By The Secretary Of The Army	Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7037680B2 (en) *	1993-09-21	2006-05-02	The United States Of America As Represented By The Secretary Of The Army	Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
WO2003012117A1 (en) *	2001-07-28	2003-02-13	The Secretary Of State For Defence	Dna vaccine
WO2006011966A1 (en)	2004-06-30	2006-02-02	Allergan, Inc.	Optimizing expression of active botulinum toxin type e
EP1773874B1 (en) *	2004-08-04	2012-10-24	Allergan, Inc.	Optimizing expression of active botulinum toxin type a
FR2889066B1 (en) *	2005-07-28	2007-11-09	Centre Nat Rech Scient	METHOD OF GENETIC IMMUNIZATION BY ELECTROTRANSFER AGAINST TOXIN AND ANTISERUM THAT CAN BE OBTAINED BY THIS PROCESS
JP2009106163A (en) *	2007-10-26	2009-05-21	Kyushu Univ	Nucleic acid sequence, vector, transformant, production method, and nucleic acid sequence primer
EP2491384B1 (en)	2009-10-21	2013-12-04	Merz Pharma GmbH & Co. KGaA	System for determining unprocessed and partially processed neurotoxin type a
GB201312317D0 (en) *	2013-07-09	2013-08-21	Syntaxin Ltd	Cationic neurotoxins
GB201407525D0 (en) *	2014-04-29	2014-06-11	Syntaxin Ltd	Manufacture of recombinant clostridium botulinum neurotoxins
CN116333068A (en)	2015-01-09	2023-06-27	益普生生物创新有限公司	Cationic neurotoxin
JP6910961B2 (en) *	2015-05-15	2021-07-28	ヌーテックベンチャーズ	Genetically engineered Clostridium botulinum toxin for molecular delivery to selected cells
AU2018389121A1 (en) *	2017-12-20	2020-07-30	Allergan, Inc.	Botulinum toxin cell binding domain polypeptides and methods of use for treatments of fibrosis associated disorders
CN110075288B (en) *	2019-05-06	2022-04-26	中国兽医药品监察所	Nontoxic C-type clostridium botulinum genetic engineering subunit vaccine and production method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9511909D0 (en) *	1995-06-12	1995-08-09	Microbiological Res Authority	Vaccine

2000
- 2000-05-12 EP EP00932296A patent/EP1180999A4/en not_active Ceased
- 2000-05-12 AU AU50035/00A patent/AU783450B2/en not_active Ceased
- 2000-05-12 JP JP2000616731A patent/JP2004512004A/en active Pending
- 2000-05-12 CA CA002371279A patent/CA2371279A1/en not_active Abandoned
- 2000-05-12 WO PCT/US2000/012890 patent/WO2000067700A2/en not_active Ceased

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BYRNE MICHAEL P ET AL: "Purification, potency, and efficacy of the botulinum neurotoxin type A biding domain from Pichia pastoris as a recombinant vaccine candidate", INFECTION AND IMMUNITY, vol. 66, no. 10, October 1998 (1998-10-01), pages 4817 - 4822, XP002301389, ISSN: 0019-9567 *
CLAYTON M A ET AL: "Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in E. coli", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 63, no. 7, July 1995 (1995-07-01), pages 2738 - 2742, XP002110803, ISSN: 0019-9567 *

Also Published As

Publication number	Publication date
WO2000067700A2 (en)	2000-11-16
JP2004512004A (en)	2004-04-22
AU5003500A (en)	2000-11-21
AU783450B2 (en)	2005-10-27
CA2371279A1 (en)	2000-11-16
WO2000067700A3 (en)	2001-02-08
EP1180999A2 (en)	2002-02-27

Publication	Publication Date	Title
ATE322251T1 (en)	2006-04-15	NEUROTOXIN IMPLANT
DK1208214T3 (en)	2007-03-19	Genes engineered bleb vaccine
NO20014323D0 (en)	2001-09-05	Vaccine
NO20071303L (en)	2001-07-27	Pharmaceutical preparations
NO20015964L (en)	2002-01-30	Therapeutic agent comprising a botulinum neurotoxin
DE60011853D1 (en)	2004-08-05	syringe
DK1514556T3 (en)	2011-10-24	Pharmaceutical compositions with botulinum toxin
IS6040A (en)	2001-08-07	Valdekoxib preparations
DE69920011D1 (en)	2004-10-14	RECOMBINANT VENEZOLANIAN-EQUINE-HORSE-ZEPHALITIS-VIRUS-VACCINE
NO20020304L (en)	2002-03-21	Preserved pharmaceutical preparations
NO992102L (en)	2000-10-31	Peptide composition, as well as pharmaceutical composition and cancer vaccine including the peptide composition
EP1180999A4 (en)	2005-03-30	RECOMBINANT VACCINE AGAINST BOTULINUM NEUROTOXIN
EP1310252A4 (en)	2009-06-10	INJECTIONS
NO20020763D0 (en)	2002-02-15	Vaccine
BR0012512B1 (en)	2011-05-17	feline calicivirus genes and vaccines notably recombinant vaccines.
DE60037189D1 (en)	2008-01-03	RECOMBINANT, SODIUM JODID SYMPORTER-CODING ADENOVIRES
DE69933647D1 (en)	2006-11-30	RECOMBINANT LYSOPHOSPHACIDIC ACID - PHOSPHATASE.
DK1372771T3 (en)	2007-05-21	injection System
ID26951A (en)	2001-02-22	MYCOPLASMA HYOPNEUMONTAE RECOMBINANT VACCINE
ATE519775T1 (en)	2011-08-15	RECOMBINANT SUBUNIT VACCINES
FR2791348B1 (en)	2007-10-05	POLYPEPTIDE Npt2B
EP1246635A4 (en)	2004-09-01	PEPTIDES DESIGNED SUPERFAMIL O- OF CONOTOXINS
EP1359932A4 (en)	2004-06-30	TIP39 POLYPEPTIDE
EP1181031A4 (en)	2005-07-20	ANTI-ANGIOGENIC PEPTIDE
EP1497307A4 (en)	2005-11-30	VACCINE WITH RECOMBINANT P.FALCIPARUM-MEROZOITPROTEIN-1 42

Legal Events

Date	Code	Title	Description
2002-01-11	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2002-02-27	17P	Request for examination filed	Effective date: 20011211
2002-02-27	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2002-02-27	AX	Request for extension of the european patent	Free format text: AL;LT;LV;MK;RO;SI
2002-06-05	RIC1	Information provided on ipc code assigned before grant	Free format text: 7C 12N 15/11 A, 7C 12N 15/63 B, 7C 07H 21/04 B, 7C 07K 5/00 B
2005-03-30	A4	Supplementary search report drawn up and despatched	Effective date: 20050210
2007-12-12	17Q	First examination report despatched	Effective date: 20071109
2011-12-03	APBK	Appeal reference recorded	Free format text: ORIGINAL CODE: EPIDOSNREFNE
2011-12-03	APBN	Date of receipt of notice of appeal recorded	Free format text: ORIGINAL CODE: EPIDOSNNOA2E
2012-02-02	APBR	Date of receipt of statement of grounds of appeal recorded	Free format text: ORIGINAL CODE: EPIDOSNNOA3E
2012-03-01	APAF	Appeal reference modified	Free format text: ORIGINAL CODE: EPIDOSCREFNE
2015-07-16	REG	Reference to a national code	Ref country code: DE Ref legal event code: R003
2015-07-20	APBT	Appeal procedure closed	Free format text: ORIGINAL CODE: EPIDOSNNOA9E
2015-08-28	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED
2015-09-30	18R	Application refused	Effective date: 20150716